参考文献/References:
[1] Aslan D,Andersen MD,Gede LB,et al.Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans[J]. Scand J Clin Lab Invest,2012,72（1）：14-22.
[2] Neer RM,Arnaud CD,Zanchetta JR,et al.Effect of parathyroid hormone （1-34） on fractures and bone mineral density in post-menopausal women with osteoporosis[J].N Engl J Med,2001,344（19）：1434-1441.
[3] Han SL,Wan SL.Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis：meta-analysis of randomised controlled trials[J].Int J Clin Pract,2012,66（2）：199-209.
[4] Yu EW,Neer RM,Lee H,et al.Time-dependent changes in skeletal response to teriparatide：escalating vs. constant dose teriparatide （PTH 1-34） in osteoporotic women[J].Bone,2011,48（4）：713-719.
[5] Michalska D,Luchavova M,Zikan V,et al.Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis[J]. Osteoporos Int,2012,23（12）：2885-2891.
[6] Shiraki M,Sugimoto T,Nakamura T.Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women[J].Osteoporos Int,2013,24（1）：219-226.
[7] Nakamura T,Sugimoto T,Nakano T,et al.Randomized Teri-paratide [human parathyroid hormone （PTH） 1-34] Once-Weekly Efficacy Research（TOWER） trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk[J]. J Clin Endocrinol Metab,2012,97（9）：3097-3106.
[8] Fujita T,Fukunaga M,Itabashi A,et al.Once-weekly injection of low-dose Teriparatide（28.2 ?滋g） reduced the risk of vertebral fracture in patients with primary osteoporosis[J]. Calcif Tissue Int,2014,94（2）：170-175.
[9] Shen L,Xie X,Su Y,et al.Parathyroid hormone versus bisphos-phonate treatment on bone mineral density in osteoporosis ther-apy：a meta-analysis of randomized controlled trials[J]. PLoS One,2011,6（10）：e26267.
[10] Cosman F,Nieves JW,Zion M,et al.Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy[J].Osteoporos Int,2008,19（4）：529-535.
[11] Finkelstein JS,Wyland JJ,Lee H,et al.Effects of teriparatide, alendronate,or both in women with postmenopausal osteoporosis[J]. J Clin Endocrinol Metab,2010,95（4）：1838-1845.
[12] Cosman F,Eriksen EF,Recknor C,et al.Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH（1-34）] in postmenopausal osteoporosis[J].J Bone Miner Res,2011,26（3）：
503-511.
[13] Tsai JN,Uihlein AV,Lee H,et al.Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis：the DATA study randomised trial[J].Lancet,2013,382（9886）：50-56.
[14] Cusano NE,Costa AG,Silva BC,et al.Therapy of osteoporosis in men with teriparatide[J].J Osteoporos,2011,2011：463675.
[15] Saag KG,Zanchetta JR,Devogelaer JP, et al.Effects of teri-paratide versus alendronate for treating glucocorticoid-induced osteoporosis：thirty-six-month results of a randomized,double-blind,controlled trial[J].Arthritis Rheum,2009,60（11）：3346-3355.
[16] Hellmeyer L,Boekhoff J,Hadji P.Treatment with teriparatide in a patient with pregnancy-associated osteoporosis[J].Gynecol Endocrinol,2010,26（10）：725-728.
[17] Choe EY,Song JE,Park KH,et al.Effect of teriparatide on preg-nancy and lactation-associated osteoporosis with multiple vertebral fractures[J].J Bone Miner Metab,2012,30（5）：596-601.
[18] Winer KK,Sinaii N,Reynolds J,et al.Long-term treatment of 12 children with chronic hypoparathyroidism：a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium[J].J Clin Endocrinol Metab,2010,95（6）：2680-2688.
[19] Sikjaer T,Rejnmark L,Rolighed L,et al.The effect of adding PTH（1-84） to conventional treatment of hypoparathyroidism：a randomized,placebo-controlled study[J].J Bone Miner Res,2011,
26（10）：2358-2370.
[20] Cusano NE,Rubin MR,McMahon DJ,et al.Therapy of hypoparathyroidism with PTH（1-84）：a prospective four-year investigation of efficacy and safety[J].J Clin Endocrinol Metab, 2013,98（1）：137-144.
[21] Cho YH,Tchan M,Roy B,et al.Recombinant parathyroid hormone therapy for severe neonatal hypoparathyroidism[J].J Pediatr,2012,160（2）：345-348.
[22] Rejnmark L,Sikjaer T,Underbjerg L,et al.PTH replacement therapy of hypoparathyroidism[J].Osteoporos Int,2013,24（5）：1529-1536.
[23] Winer KK,Zhang B,Shrader JA,et al.Synthetic human parathy-roid hormone 1-34 replacement therapy：a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism[J].J Clin Endocrinol Metab,2012,
97（2）：391-399.
[24] Gatti D,Rossini M,Viapiana O,et al.Teriparatide treatment in adult patients with osteogenesis imperfecta type Ⅰ[J].Calcif Tissue Int,2013,93（5）：448-452.
[25] Schalin-J?覿ntti C,Mornet E,Lamminen A,et al.Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia[J].J Clin Endocrinol Metab,2010,95（12）：5174-5179.
[26] Andrews EB,Gilsenan AW,Midkiff K,et al.The US postmarketing surveillance study of adult osteosarcoma and teriparatide：study design and findings from the first 7 years[J].J Bone Miner Res,2012,27（12）：2429-2437.
[27] Cipriani C,Irani D,Bilezikian JP.Safety of osteoanabolic therapy： a decade of experience[J].J Bone Miner Res,2012,27（12）：2419-2428.